rezatapopt Evidence: Trial Results and Peer-Reviewed Publications

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

1. PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation.
   Schram AM, Fellous M, LeDuke K, et al. · Future Oncol · 2025
   PubMed: PMID 40932470 · NCT04585750 · Breast Neoplasms
2. Rezatapopt: A promising small-molecule "refolder" specific for TP53Y220C mutant tumors.
   Papavassiliou KA, Vassiliou AG, Papavassiliou AG, et al. · Neoplasia · 2025
   PubMed: PMID 40543428 · NCT04585750 · Breast Neoplasms
3. Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
   Dumbrava EE, Shapiro GI, Parikh AR, et al. · N Engl J Med · 2026
   PubMed: PMID 41740031 · NCT04585750 · Breast Neoplasms
4. Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
   Carter BZ, Mak PY, Ayoub E, et al. · Blood · 2025
   PubMed: PMID 40608889 · NCT06616636 · Leukemia, Myeloid, Acute

Publications by year

2025–2026: 4 publications.

Publications by indication

Publications by journal

• Future Oncol1 paper
• Neoplasia1 paper
• N Engl J Med1 paper
• Blood1 paper

All rezatapopt publications (4)

Sources and methodology

• Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
• Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
• Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
• Data freshness: Fri, 29 May 2026 17:36:52 GMT.